Request Demo
Last update 12 Apr 2025
APR-003
Last update 12 Apr 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms- |
Target |
Action agonists |
Mechanism TLR7 agonists(Toll like receptor 7 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization  Apros Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with APR-003NCT04645797
A Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics/ Pharmacodynamics of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions
100 Clinical Results associated with APR-003
Login to view more data
100 Translational Medicine associated with APR-003
Login to view more data
100 Patents (Medical) associated with APR-003
Login to view more data
100 Deals associated with APR-003
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Colorectal Adenocarcinoma | Phase 1 | United States | Apros Therapeutics, Inc.Startup | 20 Jan 2021 |
| Liver Cancer | Phase 1 | United States | Apros Therapeutics, Inc.Startup | 20 Jan 2021 |
| Colonic Cancer | Phase 1 | - | - | 27 Nov 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 10 | idcabhicfo(mwtxfyucxj) = Between the 25 mg (n=6) and 50 mg (n=4) dose cohorts, APR003 plasma levels were low, with no dose-dependent increase in exposure. APR003 induced a transient yet robust cytokine response peaking around 6-8 hours post-dose and declining by 24 hours. After a week of recovery, all cytokines returned to baseline before the subsequent weekly dose. Cytokine induction in plasma also revealed no dose-dependency. The dose cohort combined geometric mean maximum fold induction over pre-dose of IFNa, IP-10, IL-6, and TNFa were 41-, 21-, 5-, and 2-fold on C1D1 and 107-, 28-, 6-, and 3-fold on C1D15, respectively. Comparing the cytokine levels at 6 hours on the plasma sampling days indicated slightly diminished response on C2D1 compared to C1D1; no APR003 plasma exposure accumulation or reduction was observed on C2D1. utwixtytcg (ldtquajxub ) | Positive | 07 Nov 2022 | |||
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free